The invention includes compositions comprising at least one chimeric autoantibody receptor (CAAR) specific for an autoantibody, vectors comprising the same, compositions comprising CAAR vectors packaged in viral particles, and recombinant T cells comprising the CAAR. The invention also includes methods of making a genetically modified T cell expressing a CAAR (CAART) wherein the expressed CAAR comprises a desmoglein extracellular domain.

Regulatory T cells (Treg) are engineered to express a chimeric antigen receptor (CAR), that specifically binds folate receptor beta; and are administered to an individual for treatment of inflammation at sites characterized by the presence of activated myeloid cells. Also provided are methods for utilized engineered T regulatory cells to enhance hematopoietic cell transplantation.

Materials and methods of treating a patient with type 2 diabetes mellitus, metabolic syndrome, obesity, infertility, high blood pressure, hyperthyroidism, and hypothyroidism, hyperlipidaemia, osteoporosis, osteoarthritis, hypoadrenalism, polycystic ovary syndrome, or Parkinson's disease comprising administering a therapeutically effective amount of ex vivo cultured activated peripheral blood mononuclear cells (PBMCs) to the patient. The ex vivo cultured activated cells are activated and cultured in a presence of a cytokine and may be autologous or allogeneic relative to the patient.

Mesenchymal stromal cells are engineered to express a chimeric antigen receptor (CAR), that specifically binds a marker of activated myeloid cells, including without limitation folate receptor beta; and are administered to an individual for treatment of inflammation at sites characterized by the presence of activated myeloid cells.

Embodiments of various aspects described herein are directed to methods and compositions for producing a tolerognic or immunosuppressive dendritic cell. In particular, an immunosuppressive dendritic cell can be produced by contacting a dendritic cell with an agent that stimulates the IL 27/ectonucleotidase CD39 axis signaling. In some embodiments, the methods and/or compositions described herein can be used for treating an autoimmune disease or disorder, e.g., but not limited to multiple sclerosis (MS) and type 1 diabetes.

The invention provides a fusion protein for use in the treatment of HvG disease in a patient having received a transplant, for use in suppressing the host's immune response directed against the transplant. The fusion protein is adapted for use in suppressing the immune rejection of a transplant which contains or expresses HLA-A*02 or SLA-01*0401 in a recipient patient who is negative for HLA-A*02 or SLA-01*0401, i.e. the patient prior to transplantation does not express HLA-A*02 or SLA-01*0401. The fusion protein is a chimeric antigen receptor (CAR), which upon expression in regulatory T-cells (T.sub.reg) causes a specific suppressor activity of the regulatory T-cells in the presence of HLA-A*02 or SLA-01*0401.

The present invention describes a method of treating, preventing, reducing the likelihood of or alleviating a symptom of Alzheimer's disease and associated conditions by increasing OPN expression. The invention further provides for a method of improving cognitive function in a subject in need thereof.

The present invention describes a method of treating, preventing, reducing the likelihood of or alleviating a symptom of Alzheimer's disease and associated conditions by increasing OPN expression. The invention further provides for a method of improving cognitive function in a subject in need thereof.

The present disclosure relates to a soluble CD52 glycoprotein and its use in treating diseases regulated by effector T-cells, for example autoimmune diseases such as type I diabetes. The present disclosure also relates to fusion proteins comprising the soluble glycoprotein, to cells expressing high levels of CD52, and to diagnostic methods based on the detection of CD52 expression levels in a subject.

The present invention provides compositions, devices, and methods for the coordinated delivery of transplant material and immune suppressors for control of transplant rejection. In particular embodiments, immune suppression cells (e.g., regulatory T cells) and transplant material (e.g., cells, tissue, etc.) are provided within a delivery scaffold for transplant into a subject.